Biochemically compared with other DNMT3A mutations, R882 mutations show additional dominant-negative and gain-of-function activities, suggesting different biological mechanism of action and possible unique clinicopathologic features in DNMT3A mutant MNs. This evidence concerns the gene DNMT3A and Melnick-Needles syndrome.